Literature DB >> 34462555

Prevalence of hyperhomocysteinemia (HHcy) and its major determinants among hypertensive patients over 35 years of age.

Minna Cheng1, Hong Xue2, Xinjian Li3, Qinghua Yan3, Dingliang Zhu4, Yan Wang4, Yan Shi5,6, Chen Fu7.   

Abstract

OBJECTIVE: Hyperhomocysteinemia (HHcy) and hypertension are associated with cardiovascular events. However, effects of Hcy-lowing interventions on cardiovascular outcome were conflicting. Serum folate level was proposed to be a possible determinant of efficacy of extra folate supplementation on cardiovascular outcome. The aims of the present study were to describe representative information on the levels of serum homocysteine and folate in hypertensive patients, and to explore the major determinants of HHcy.
METHODS: 11,007 participants with hypertension were analyzed in this cross-sectional study. Blood pressure and serum levels of biochemical indicators were measured. Multivariate logistic regression model was used to assess the associated factors of HHcy.
RESULTS: Geometric mean of serum total homocysteine was 14.1 (95% CI: 13.9, 14.4) μmol/L and prevalence of HHcy was 36.1 (95% CI: 34.0, 38.1) % in hypertensive patients. HHcy was strongly associated with factors including male sex, older age, elevated serum creatinine (SCr), lower serum folate and vitamin B12, and uncontrolled blood pressure in hypertensive patients. Elevated SCr attributed to HHcy with the etiologic fraction of 0.29. The change of the odds ratio of HHcy associated with folate was significantly higher in patients with elevated SCr compared with that of patients with normal SCr.
CONCLUSION: The results suggested the protection of female sex and higher levels of folate and vitamin B12 from HHcy and attribution of older age and elevated SCr to HHcy. Restoring renal function deserved attention for hypertensive patients to benefit from Hcy-lowing measures.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34462555     DOI: 10.1038/s41430-021-00983-6

Source DB:  PubMed          Journal:  Eur J Clin Nutr        ISSN: 0954-3007            Impact factor:   4.016


  44 in total

Review 1.  Homocysteine-lowering interventions for preventing cardiovascular events.

Authors:  Arturo J Martí-Carvajal; Ivan Solà; Dimitrios Lathyris; Mark Dayer
Journal:  Cochrane Database Syst Rev       Date:  2017-08-17

2.  Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991-1994): population reference ranges and contribution of vitamin status to high serum concentrations.

Authors:  J Selhub; P F Jacques; I H Rosenberg; G Rogers; B A Bowman; E W Gunter; J D Wright; C L Johnson
Journal:  Ann Intern Med       Date:  1999-09-07       Impact factor: 25.391

3.  Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial.

Authors:  Yong Huo; Jianping Li; Xianhui Qin; Yining Huang; Xiaobin Wang; Rebecca F Gottesman; Genfu Tang; Binyan Wang; Dafang Chen; Mingli He; Jia Fu; Yefeng Cai; Xiuli Shi; Yan Zhang; Yimin Cui; Ningling Sun; Xiaoying Li; Xiaoshu Cheng; Jian'an Wang; Xinchun Yang; Tianlun Yang; Chuanshi Xiao; Gang Zhao; Qiang Dong; Dingliang Zhu; Xian Wang; Junbo Ge; Lianyou Zhao; Dayi Hu; Lisheng Liu; Fan Fan Hou
Journal:  JAMA       Date:  2015-04-07       Impact factor: 56.272

Review 4.  Genetics of homocysteine metabolism and associated disorders.

Authors:  S Brustolin; R Giugliani; T M Félix
Journal:  Braz J Med Biol Res       Date:  2009-12-04       Impact factor: 2.590

5.  Homocysteine lowering and cardiovascular events after acute myocardial infarction.

Authors:  Kaare Harald Bønaa; Inger Njølstad; Per Magne Ueland; Henrik Schirmer; Aage Tverdal; Terje Steigen; Harald Wang; Jan Erik Nordrehaug; Egil Arnesen; Knut Rasmussen
Journal:  N Engl J Med       Date:  2006-03-12       Impact factor: 91.245

6.  Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis.

Authors:  David S Wald; Malcolm Law; Joan K Morris
Journal:  BMJ       Date:  2002-11-23

7.  High-dose B vitamin supplementation and progression of subclinical atherosclerosis: a randomized controlled trial.

Authors:  Howard N Hodis; Wendy J Mack; Laurie Dustin; Peter R Mahrer; Stanley P Azen; Robert Detrano; Jacob Selhub; Petar Alaupovic; Chao-ran Liu; Ci-hua Liu; Juliana Hwang; Alison G Wilcox; Robert H Selzer
Journal:  Stroke       Date:  2008-12-31       Impact factor: 7.914

8.  Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial.

Authors:  Guido Schnyder; Marco Roffi; Yvonne Flammer; Riccardo Pin; Otto Martin Hess
Journal:  JAMA       Date:  2002-08-28       Impact factor: 56.272

9.  Homocysteine and stroke: evidence on a causal link from mendelian randomisation.

Authors:  Juan P Casas; Leonelo E Bautista; Liam Smeeth; Pankaj Sharma; Aroon D Hingorani
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

10.  Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study.

Authors:  Wouter de Ruijter; Rudi G J Westendorp; Willem J J Assendelft; Wendy P J den Elzen; Anton J M de Craen; Saskia le Cessie; Jacobijn Gussekloo
Journal:  BMJ       Date:  2009-01-08
View more
  2 in total

1.  Homocysteine Solution-Induced Response in Aerosol Jet Printed OECTs by Means of Gold and Platinum Gate Electrodes.

Authors:  Pasquale D'Angelo; Mario Barra; Patrizia Lombari; Annapaola Coppola; Davide Vurro; Giuseppe Tarabella; Simone Luigi Marasso; Margherita Borriello; Federico Chianese; Alessandra F Perna; Antonio Cassinese; Diego Ingrosso
Journal:  Int J Mol Sci       Date:  2021-10-25       Impact factor: 5.923

2.  Hyperhomocysteinemia Promotes Cardiac Hypertrophy in Hypertension.

Authors:  Yawen Deng; Zhitong Li; Xiangbo An; Rui Fan; Yao Wang; Jiatian Li; Xiaolei Yang; Jiawei Liao; Yunlong Xia
Journal:  Oxid Med Cell Longev       Date:  2022-08-22       Impact factor: 7.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.